J&J | JNJ - Interest Expense On Debt


J&J reported $43M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Abbott USD 68M 26M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Baxter International USD 58M 14M Sep/2025
Bayer EUR 675M 87M Dec/2025
Becton, Dickinson and Co. USD 149M 4M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
Boston Scientific USD 90M 0 Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
CONMED USD 7.06M 310K Mar/2026
Cooper Companies USD 20.9M 1.5M Mar/2026
Dexcom USD 4.2M 500K Dec/2025
Edwards Lifesciences USD 35.9M 2.7M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Globus Medical USD 5.44B 5.44B Mar/2026
Insulet USD 14.7M 5.5M Mar/2026
Integra LifeSciences USD 22.46M 1.21M Mar/2026
Intuitive Surgical USD 20.11B 58.39B Mar/2026
J&J USD 43M 25M Mar/2026
Medtronic USD 176M 5M Mar/2026
Merck USD 479M 67M Mar/2026
Merit Medical Systems USD 6.53M 162K Mar/2026
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Stryker USD 46.29B 45.68B Mar/2026
Tandem Diabetes Care USD 1.15B 1.15B Mar/2026
Teva Pharmaceutical Industries USD 216M 4M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Zimmer Biomet Holdings USD 68.8M 3.1M Mar/2026
Zoetis USD 62M 5M Mar/2026